Quanterix Corporation (QTRX - Free Report) announced its inaugural collaborations with health systems to revolutionize Alzheimer’s disease (AD) diagnosis. By partnering with AdventHealth, Mass General Brigham, Mayo Clinic, SC-ADRC and UPMC, Quanterix is set to enhance AD testing accessibility, thereby impacting millions of patients across 18 states.
The financial terms of the collaborations have not been revealed.
More on the News
The collaborations will cover more than 140 hospitals across 18 states, serving approximately 21 million patients. This will mark a substantial expansion in clinical access to Quanterix's cutting-edge blood biomarker assays for AD. This expanded access promises to bridge the gap between traditional diagnostic methods and the pressing need for accurate, non-invasive AD testing.
Transforming Diagnosis Landscape
Traditionally, AD diagnosis relies on invasive procedures and costly biomarker detection methods, leaving a significant portion of patients undiagnosed or misdiagnosed.This inaccessibility has left 50-70% of symptomatic AD patients without a correct and timely diagnosis, impacting the quality of life, medical autonomy and general well-being.
Quanterix's blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis. The adoption of Quanterix's Simoa p-Tau 217 assays promises high accuracy and accessibility, revolutionizing the AD diagnosis landscape.
Optimism in Patient Care
The collaborative efforts between Quanterix and these renowned healthcare institutions have sparked optimism in AD patient care. Driven by simplified, affordable and non-invasive testing methods, physicians can now proactively evaluate and monitor patients with memory concerns, significantly enhancing diagnostic accuracy and timely interventions.
Huge Market Prospects
Per Quanterix, 15 million Americans are predicted to be affected by Alzheimer’s by 2060. Highly accurate and easily accessible blood testing will play a critical role in the early detection and treatment of Alzheimer’s. Quanterix's strategic collaborations underscore its commitment to establishing the industry standard for AD testing, positioning the company as a pivotal player in the global fight against Alzheimer's.
Share Price Performance
Shares of QTRX have risen a stupendous 128.3% compared with the industry’s 7.8% growth.
Zacks Rank and Key Picks
The stock carries a Zacks Rank #3 (Hold) currently.
Some better-ranked stocks in the broader medical space are Cardinal Health (CAH - Free Report) , DaVita (DVA - Free Report) and Insulet (PODD - Free Report) . Cardinal Health and DaVita sport a Zacks Rank #1 (Strong Buy) each, while Insulet carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cardinal Health’s stock has risen 13.3% in the past year. Earnings estimates for CAH have increased from $6.91 to $7.28 for fiscal 2024 and from $7.74 to $8.02 for fiscal 2025 in the past 30 days.
CAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 15.6%. In the last reported quarter, it delivered an earnings surprise of 16.7%.
Estimates for DaVita’s 2023 earnings per share have increased from $8.86 to $8.97 in the past 30 days. Shares of the company have risen 7.4% in the past year compared with the industry’s growth of 2.9%.
DVA’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 35.6%. In the last reported quarter, it delivered an earnings surprise of 22.2%.
Estimates for Insulet’s 2023 earnings per share have increased from $2.54 to $2.56 in the past 30 days. Shares of the company have decreased 34.7% in the past year against the industry’s increase of 7.2%.
PODD’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 100.1%. In the last reported quarter, it delivered an earnings surprise of 108.9%.
Disclaimer: This article has been written with the assistance of Generative AI. However, the author has reviewed, revised, supplemented, and rewritten parts of this content to ensure its originality and the precision of the incorporated information.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
Quanterix Corporation (QTRX - Free Report) announced its inaugural collaborations with health systems to revolutionize Alzheimer’s disease (AD) diagnosis. By partnering with AdventHealth, Mass General Brigham, Mayo Clinic, SC-ADRC and UPMC, Quanterix is set to enhance AD testing accessibility, thereby impacting millions of patients across 18 states.
The financial terms of the collaborations have not been revealed.
More on the News
The collaborations will cover more than 140 hospitals across 18 states, serving approximately 21 million patients. This will mark a substantial expansion in clinical access to Quanterix's cutting-edge blood biomarker assays for AD. This expanded access promises to bridge the gap between traditional diagnostic methods and the pressing need for accurate, non-invasive AD testing.
Transforming Diagnosis Landscape
Traditionally, AD diagnosis relies on invasive procedures and costly biomarker detection methods, leaving a significant portion of patients undiagnosed or misdiagnosed.This inaccessibility has left 50-70% of symptomatic AD patients without a correct and timely diagnosis, impacting the quality of life, medical autonomy and general well-being.
Quanterix's blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis. The adoption of Quanterix's Simoa p-Tau 217 assays promises high accuracy and accessibility, revolutionizing the AD diagnosis landscape.
Optimism in Patient Care
The collaborative efforts between Quanterix and these renowned healthcare institutions have sparked optimism in AD patient care. Driven by simplified, affordable and non-invasive testing methods, physicians can now proactively evaluate and monitor patients with memory concerns, significantly enhancing diagnostic accuracy and timely interventions.
Huge Market Prospects
Per Quanterix, 15 million Americans are predicted to be affected by Alzheimer’s by 2060. Highly accurate and easily accessible blood testing will play a critical role in the early detection and treatment of Alzheimer’s. Quanterix's strategic collaborations underscore its commitment to establishing the industry standard for AD testing, positioning the company as a pivotal player in the global fight against Alzheimer's.
Share Price Performance
Shares of QTRX have risen a stupendous 128.3% compared with the industry’s 7.8% growth.
Zacks Rank and Key Picks
The stock carries a Zacks Rank #3 (Hold) currently.
Some better-ranked stocks in the broader medical space are Cardinal Health (CAH - Free Report) , DaVita (DVA - Free Report) and Insulet (PODD - Free Report) . Cardinal Health and DaVita sport a Zacks Rank #1 (Strong Buy) each, while Insulet carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cardinal Health’s stock has risen 13.3% in the past year. Earnings estimates for CAH have increased from $6.91 to $7.28 for fiscal 2024 and from $7.74 to $8.02 for fiscal 2025 in the past 30 days.
CAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 15.6%. In the last reported quarter, it delivered an earnings surprise of 16.7%.
Estimates for DaVita’s 2023 earnings per share have increased from $8.86 to $8.97 in the past 30 days. Shares of the company have risen 7.4% in the past year compared with the industry’s growth of 2.9%.
DVA’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 35.6%. In the last reported quarter, it delivered an earnings surprise of 22.2%.
Estimates for Insulet’s 2023 earnings per share have increased from $2.54 to $2.56 in the past 30 days. Shares of the company have decreased 34.7% in the past year against the industry’s increase of 7.2%.
PODD’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 100.1%. In the last reported quarter, it delivered an earnings surprise of 108.9%.
Disclaimer: This article has been written with the assistance of Generative AI. However, the author has reviewed, revised, supplemented, and rewritten parts of this content to ensure its originality and the precision of the incorporated information.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
Get the latest research report on DVA - FREE
Get the latest research report on CAH - FREE
Get the latest research report on PODD - FREE
Get the latest research report on QTRX - FREE